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ABSTRAK 
 
Objektif: Untuk menyiasat sama ada rawatan kombinasi dengan menggunakan 
madu Tualang dapat mempengaruhi background parenchymal enhancement 
(BPE) payudara dalam pengimejan resonans magnet di kalangan wanita putus 
haid yang menghidapi penyakit kanser payudara yang menerima rawatan 
anastrozole. 
 
Metodologi: Seramai 22 pesakit dari Klinik Onkologi, Hospital USM, Kubang 
Kerian, Kelantan terlibat dalam kajian ini. Mereka dibahagikan dalam dua 
kumpulan, iaitu kumpulan kawalan (1mg anastrozole sekali sehari) dan 
kumpulan intervensi (1 mg anastrozole sekali sehari + 20 mg TH sekali sehari). 
Mereka termasuk wanita putus haid yang menghidapi penyakit kanser payudara 
unilateral pada peringkat I, II dan III dengan reseptor estrogen (ER) atau 
reseptor progesteron (PgR) positif dan menerima anastrazole sebagai rawatan 
kurang atau tidak lebih daripada satu tahun. BPE payudara contralateral 
sebelum dan 6 bulan selepas rawatan telah dibandingkan sebelah menyebelah 
menggunakan ujian statistik. 
 
Keputusan: 10% daripada wanita yang menerima rawatan anastrozole telah 
menunjukkan penurunan BPE payudara dari kategori sederhana ke kategori 
ringan (p = 0.317). 42% daripada wanita yang menerima rawatan kombinasi 
anastrozole dan TH telah menunjukkan pengurangan BPE (p = 0.034). 
Penurunan BPE ke satu kategori berlaku dalam empat wanita, manakala 
penurunan sebanyak dua kategori berlaku dalam seorang wanita. 
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Kesimpulan: Rawatan kombinasi TH dan anastrozole adalah lebih berkesan 
berbanding dengan penggunaan anastrazole sahaja dalam mengurangkan BPE 
dikalangan pesakit kanser payudara menopaus dengan ER atau PgR positif. 
dan dengan itu mengurangkan risiko berulangnya kanser..Penemuan kajian ini 
meningkatkan lagi nilai TH dalam bidang perubatan. 
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ABSTRACT 
Objective: To investigate whether the combination treatment with Tualang 
honey (TH) influences the background parenchymal enhancement (BPE) at 
breast magnetic resonance imaging (MRI) in postmenopausal women with 
history of breast cancer treated with anastrozole. 
Methodology: A total of 22 patients were recruited for both control (1 mg 
anastrozole daily) and intervention (1 mg anastrozole daily + 20 mg TH daily) 
groups from Oncology Clinic, Hospital USM, Kubang Kerian, Kelantan. 
Inclusive criteria included postmenopausal women with unilateral breast cancer 
stages I, II, or III, oestrogen receptor (ER) positive and/or progesterone 
receptor (PgR) positive and receiving anastrazole as treatment for or less a 
year were included. The BPE of contralateral breast before and 6 months after 
treatment was compared side by side using sign test. 
Results: A decrease in BPE was noted in 10% of women (p = 0.317) on 
anastrozole treatment, resulted in a category change of BPE from moderate to 
mild. The combination of anastrozole and TH treatment showed a decrease in 
BPE in 42% (p = 0.034) of postmenopausal breast cancer women. BPE 
decreased by one category of assessment in four women and by two 
categories of assessment in one woman.  
Conclusions: The combination of TH and anastrozole is more efficacious than 
anastrozole alone in decreasing breast BPE of ER-positive postmenopausal 
breast cancer women and thus reducing the risk of cancer recurrence. These 
findings further support the medicinal value of TH. 
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1.0 INTRODUCTION& LITERATURE REVIEW 
 Globally an estimated 1.6 million new cases of breast cancer are 
diagnosed every year with an estimated 560,000 death in 2015 (World Health 
Organization, 2015). Breast cancer is the leading cause of death among 
Malaysian women (National Cancer Registry of Malaysia 2005-2007). 
Approximately 5,000 Malaysian women are diagnosed with breast cancer every 
year, most of whom aged between 30 and 60 years, while approximately 50% 
of those affected are under 50-years of age (Lim et al., 2008). 
 Annual breast MRI is often considered in many of these women for high-
risk screening and/or surveillance. Approximately three-quarters of all invasive 
breast cancers are hormone receptor positive. The main stay of treatment for 
these oestrogen and/or progesterone receptor–positive breast cancers is 
endocrine therapy. In postmenopausal women with hormone receptor–positive 
disease, aromatase inhibitors (AIs) (eg, anastrozole) have become a standard 
of care as an adjuvant treatment aimed in preventing tumor relapse. 
 Treatment with these agents has been associated with decreased 
recurrence rates and greater disease-free survival than treatment with 
tamoxifen, a selective oestrogen receptor modulator with a different mechanism 
of action (Howell et al., 2005). The adjuvant treatment with anastrozole or 
letrozole is associated with visible decreases in BPE in postmenopausal breast 
cancer survivors. These results provide support for the hormone sensitivity of 
BPE and suggest it has potential to be investigated as a marker of hormonal 
treatment response (King et al., 2012). 
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 However, several adverse events are reported in patients treated with 
anastrozole including increases the risk of osteoporosis, falls, and fractures in 
women affected (Chen et al., 2005a, Chen et al., 2005b, Kanis et al., 1999). 
Many authors suggested that honey, which is produced from complex 
enzymatic process of nectar and saccharine exudates collected from various 
kinds of floral sources (Ball, 2007) has high antioxidant activity (Yao, 2003, 
Iurlina, 2009, Pyrzynska, 2009) and potential to prevent development of cancer 
(Valko et al., 2007).  
 Phytochemical available in honey can be narrowed down into phenolic 
acids and polyphenols. Variants of polyphenols in honey are reported to have 
antiproliferative property against several types of cancer (Jaganathan and 
Mandal, 2009). TH is a wild jungle honey produced by Apis dorsata bees which 
make hives on tall Kompassiaexcelsa (Tualang) trees of tropical rainforests 
(Tan et al., 2009, Nasir et al., 2010). TH is reported to have positive modulation 
effects on carcinogen 7,12-dimethylbenz(α)anthracene in rats-induced breast 
cancers in rats in preliminary study (Kadir et al., 2013). 
 Therefore, this study is aimed to investigate whether combination 
treatment with TH influences BPE at breast MRI in postmenopausal women 
with prior history of breast cancer treated with anastrozole. 
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1.1 LITERATURE REVIEW 
1.1.1 Background Parenchymal Enhancement (BPE) 
 Magnetic resonance imaging (MRI) of the breast is a useful tool for the 
detection and characterization of breast disease, assessment of local extent of 
the disease, evaluation of treatment response, and guidance for biopsy and 
localization. MRI findings should be correlated with clinical history, physical 
examination results, and the results of mammography and any other prior 
breast imaging. 
 Lesion detection at contrast material–enhanced breast MRI is primarily 
based on a lesion’s vascularity relative to normal breast tissue. Diagnostic 
criteria for lesion assessment and management include both morphologic 
features and enhancement kinetics. Normal breast tissue can also enhance on 
MR imaging, and this enhancement of normal breast tissue is termed BPE. 
Normal BPE can be classified as minimal (<25% of glandular tissue 
demonstrating enhancement), mild (25%–50% enhancement), moderate (50%–
75% enhancement), or marked (>75% enhancement) (Morris, 2007).  
 Kuhl (2007) listed a number of general factors that affect the degree and 
amount of tissue enhancement: the amount or concentration of the contrast 
agent (although the effects may not be linear), T1-weighted contrast of the 
pulse sequence used, baseline T1-weighted relaxation times of different breast 
tissues, inherent T1-weighted relaxivity of the contrast agent, and diffusion rate 
of the contrast agent. Specifically within the breast, the anatomy of the 
mammary vascular system and hormonal influences on the mammary tissue 
also affect the pattern and degree of BPE. 
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 Endocrine therapy with anti-hormonal treatment that includes selective 
oestrogen receptor modulators or aromatase inhibitors is an important part of 
treating oestrogen/progesterone receptor-positive tumors. Because these 
agents act as anti-oestrogenic agents, they can decrease hormonal stimulation 
of the normal background breast tissue. King et al. (2012) have evaluated the 
effects of aromatase inhibitors on BPE, and their study demonstrated a 
decrease in BPE in 33.9% of postmenopausal patients with cancer that was 
treated with aromatase inhibitors. Investigators in a separate pilot study (Mousa 
et al., 2012) evaluated the effect of high-dosage aromatase inhibitors on BPE in 
healthy postmenopausal women. They performed breast MR imaging 
examinations before and after 3 days of high-dosage aromatase inhibitor 
therapy and reported a statistically significant decline in the degree of BPE after 
treatment. 
 
1.1.2 Anastrozole 
 In the late 1970’s, after a discovery that aminoglutethimide, an anti-
convulsant, leads to adrenal insufficiency and suppresses estrogen synthesis 
via aromatase inhibition (Santen et al., 1978), it was developed for the 
treatment of metastatic breast cancer (Smith et al., 1978). Aromatase inhibitors 
suppress plasma estradiol levels in postmenopausal women by inhibiting the 
enzyme aromatase responsible for the conversion of andronstenedione to 
oestrone and testosterone to estradiol. Efforts to improve the efficacy and 
therapeutic index of this class of drugs lead to the development of the current 
significantly more specific third generation aromatase inhibitors: anastrozole, 
letrozole, and exemestane. The third generation aromatase inhibitors are 
divided into two major types, namely type I and type II inhibitors. The type I 
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inhibitors e.g. exemestane, are steroidal analogues of androstenedione and 
bind irreversibly to the same site on the aromatase molecule resulting in 
enzyme inactivation. Conversely, the type II inhibitors e.g. anastrozole and 
letrozole are non-steroidal in nature and bind reversibly to the heme group of 
the enzyme (Smith and Dowsett, 2003). Because of this reversible interaction 
with the enzyme, anastrozole must be constantly present to result in aromatase 
inhibition (Buzdar, 2003). 
 To reduce the early risk of relapse that often occurs in breast cancer 
patients after surgery, it is important to identify more effective adjuvant 
treatments. The Arimidex, Tamoxifen, Alone or in combination is the most 
significant multicenter prospective double-blinded randomized clinical trial 
undertaken to compare the up-front use of anastrozole, tamoxifen, or a 
combination of the two drugs, in postmenopausal women with early localized 
operable breast cancer with an intention to treat analysis. Initial analysis of the 
trial, performed at 33 months of median follow-up, exhibited no differences 
between the groups that received the combination tamoxifen and anastrozole or 
tamoxifen alone (Baum et al., 2002). Further analysis was conducted at 47 
months of median follow-up, after completion of the five years’ adjuvant 
treatment (Howell et al., 2005) and at 100 months of median follow-up (Forbes 
et al., 2008). Since the earliest time points, it appeared clear that anastrozole 
was more efficacious than tamoxifen in prolonging disease free survival, time to 
relapse and in reducing the incidence of contralateral breast cancer. 
 Tamoxifen has the advantage of protecting postmenopausal women from 
bone loss, but increases the risk of developing thromboembolic disorders or 
gynecologic complications such as hot flushes, vaginal bleeding and discharge 
or endometrial cancer. These major side effects associated with tamoxifen were 
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significantly lower in the patients treated with anastrozole. The major 
disadvantage of anastrozole therapy lies in the increased incidence of fracture 
episodes, especially of the spine (Baum et al., 2002). Interestingly, the increase 
in the number of yearly fractures was observed only during the actual 
anastrozole treatment, whereas in the post treatment follow-up period there 
were no significant differences between the anastrozole and tamoxifen 
treatment groups (Forbes et al., 2008). 
 
1.1.3 Honey 
 Honey is the substance made when the nectar and sweet deposits from 
plants are gathered, modified and stored in the honeycomb by honey bees. 
Honey is composed of a complex mixture of water, carbohydrates and a myriad 
of other minor compounds (White, 1978). The chemical composition of honey is 
variable and depends on regional and climatic conditions and on the type of 
flowers visited by the bees, thus, its classification as unifloral or polyfloral. 
However, on average, natural honey is composed of 17.1% water, 82.4% 
carbohydrates, approximately 38.5% fructose, 31% glucose and 12.9 % other 
sugars and 0.5% proteins, amino acids, vitamins, phenolic compounds, organic 
acids and multiple minerals, among other minority constituents (White, 1978, 
García, 1986, Moreira, 2001, Fredes, 2006, Khan et al., 2007, Montenegro, 
2008). 
 In natural honey, as well as in propolis and royal jelly, most of the 
phenolic compounds are present in the form of flavonoids (Viuda-Martos, 2008), 
a vast family of phytochemicals comprising chalcones, flavandiols, flavonols, 
anthocyanins and proanthocyanidins. Flavonoid biosynthesis derived from the 
phenylpropanoid pathway, one of the most widely studied secondary metabolic 
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routes in plant systems. Several phenolic compounds, especially flavonoids, are 
associated with multiple benefits on human health, including anti-inflammatory, 
anti-oxidant, anti-allergic, anti-thrombotic, anti-diabetogenic, hypoglycemic, 
normolipidemic, hepato-protective, anti-viral and anti-carcinogenic activities 
(Havsteen, 2002, Middleton et al., 2000, Pérez-Trueba, 2003). 
 Breast cancer is the major cause of cancer deaths among women 
globally. Besides several other factors, the circulating levels of estrogens and 
dysregulated estrogen signaling pathways play a predominant role in the 
development and progression of breast cancer (Germain, 2011). As a result, 
breast cancer therapy often targets the estrogen receptor (ER)-signaling 
pathway. There have been some attempts to investigate if honey could 
modulate this important pathway. Tsiapara and colleagues evaluated the 
potential of Greek thyme, pine and fir honey extracts to modulate the estrogenic 
activity and cell viability of breast cancer cells (MCF-7) (Tsiapara, 2009). The 
authors found that the honey samples exhibited a biphasic activity in MCF-7 
cells depending on the concentration an anti-oestrogenic effect at low 
concentrations and an estrogenic effect at high concentrations. In the presence 
of estradiol, thyme and pine honey extracts were found to antagonize oestrogen 
activity, while fir honey extract enhanced estrogen activity in MCF-7 cells. The 
study also reported variations on the effects of the three honey extracts on cell 
viability. While the study found no effect of thyme and pine honey on MCF-7 
cells, fir honey enhanced the viability of MCF-7 cells. These dual effects of 
honey extracts are mostly likely due to their high contents of phenolic 
compounds such as kaempferol and quercetin. Phenolic compounds are 
phytoestrogens which exert dual action both inhibitory and stimulatory effects 
(Kyselova, 2011). Phytoestrogens are phytochemicals which are structurally 
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similar to mammalian oestrogens and therefore can bind to oestrogen receptors 
(Patisaul and Jefferson, 2010). They can elicit oestrogenic or anti-oestrogenic 
effect depending on certain factors such as its concentration (Patisaul and 
Jefferson, 2010, Ziegler, 2004). 
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2.0 STUDY PROTOCOL 
2.1 Document Submitted for Ethical Approval 
Title: 
Magnetic Resonance Imaging Evaluation of the Effect of Tualang Honey (TH) in 
Breast Tissue among Breast Cancer Patient Treated with anastrozole in HUSM 
 
General objective: 
The aim of this study is to investigate if treatment with TH influences BPE at 
breast MRI in postmenopausal women with prior history of breast cancer 
treated with anastrozole. 
 
Specific objectives: 
1. To investigate change of BPE in pre and post therapy in control group (on 
anastrozole) 
2. To investigate changes of BPE in intervention group (anastrozole with TH). 
3. To compare changes of BPE between controlled and intervention group 
 
Study Hypothesis: 
TH decreases the BPE in postmenopausal breast cancer survivors with 
administration of anastrazole. 
 
 
 
 
 
 
13 
 
Methodology: 
This is a randomized controlled trial for six months duration which will be 
conducted in Oncology Clinic, Hospital USM, Kubang Kerian, Kelantan. 
 
Study population: 
All volunteered breast cancer patient receiving adjunct chemo-adjuvant 
hormonal therapy  
Inclusion criteria: 
1. Postmenopausal women with unilateral breast cancer patients;  
stages I to III 
2. Have HPE result available to confirm the diagnosis 
3. Having ER positive and/or PgR positive 
4. Receiving Anastrazole treatment with maximum of 1 years 
 
Exclusion criteria: 
1. History of allergy to TH 
2. Receiving hormone replacement therapy  
3. On over the counter supplement - e.g honey, herbs,  
4. Liver or renal impairment 
 
Sampling technique: 
Randomization method based on block of four using computer generated 
program will be applied for sampling. 
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Sample size: 
Based on study by King et.al.,2012 
Sample size calculation done by dichotomous variable using G*Power Software 
Calculation version 3.1.3 (Germany),  
Input: 
α = 0.05 
power = 0.9 
Effect size = 0.3 (% of decrease BPE in anastrozole (control group) 
Constant proportion = 0.5 (% of expected result decreased BPE in TH 
(intervention group) 
n= 28 
The highest calculated sample size was 28. However after considering a 20% 
drop-out, the final sample size for each group is 31 
 
Research tool: 
MRI Philips Achieva 3.0T X-Series  
 
Study protocol: 
1. Subjects were screened against the inclusion/exclusion criteria. Subjects 
who agreed to participate will be asked to sign written informed consent 
forms. They were informed to come again in the 2 weeks time for the 
MRI appointment. 
2. Patient were randomised based on blocks of 4 for two groups 
(anastrozole group/ control group) and anastrozole with TH (intervention 
group) using a computer generated program. 
i. Group 1 (control group: Subject receiving anastrozole 1 mg daily (po) 
15 
 
ii. Group 2 (intervention group) : Subject receiving anastrozole 1 mg daily 
and  TH supplement of 20 gram daily. The choice of the dose of TH in 
this study is based on the study conducted by Nik Hazlina et.al. (2012). 
 
Data Collection: 
 During visit 1 (baseline) for the postmenopausal breast cancer patient on 
anastrozole the baseline of contrast enhanced MRI breast was performed using 
MRI Philips Achieva 3.0T X-Series. All patients must immediately report if 
adverse event occurs. Each patient was given opportunity to ask any queries 
regarding the study. MRI breast were reported by a consultant breast radiologist 
with 11 year experience. 
 At visit 2 (month six), repeat contrast enhanced MRI breast was 
performed  and any adverse event were assessed. Patient were informed about 
study completion and advised to continue normal routine follow-up. Patients are 
allowed to withdraw from the study at any point of the study. 
Compliance: 
In order to ensure compliance of honey and anastrozole, subject will be 
educated regarding the importance of compliance to the supplement and 
anastrozole.  Subjects will be given a diary and phone calls made every month 
to ensure compliance.  
TH was supplied every 2 monthly. 
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3.0 MANUSCRIPT 
3.1 Abstract 
Objective: To investigate whether the combination of anastrozole and Tualang 
honey (TH) influences background parenchymal enhancement (BPE) in breast 
magnetic resonance imaging (MRI) of postmenopausal women with a history of 
breast cancer who were treated with anastrozole. 
Methodology: A total of 22 patients were recruited from the Oncology Clinic, 
Hospital Universiti Sains Malaysia, Kelantan. The patients were divided into the 
control (anastrozole 1 mg daily) and intervention (anastrozole 1 mg daily + TH 
20 mg daily) groups. The inclusion criteria were postmenopausal women with 
stage I, II, or III unilateral breast cancer; with estrogen receptor (ER)-positive 
and/or progesterone receptor (PgR)-positive disease; and who received 
anastrozole treatment for one year or less. The BPE of the contralateral breast 
before and six months following treatment was compared using the sign test. 
Results: There was a decrease in BPE in 10% of the women (p=0.317) who 
received only anastrozole, which resulted in a change of BPE category from 
moderate to mild. However, the combination of anastrozole and TH evoked a 
decrease in BPE in 42% of the patients (p=0.034), among which BPE 
decreased by one category of assessment in four women and by two categories 
of assessment in one woman.  
Conclusions: The combination of TH and anastrozole is more efficacious than 
anastrozole alone in decreasing breast BPE of postmenopausal women with 
ER-positive breast cancer and thus reducing the risk of cancer recurrence. 
These findings support the medicinal value of TH as an adjuvant treatment to 
anastrozole.  
17 
 
3.2 Introduction 
 Globally, it is estimated that 1.6 million new cases of breast cancer are 
diagnosed every year, with 560,000 fatalities (World Health Organization, 
2015). Breast cancer is the leading cause of death among Malaysian women 
(National Cancer Registry of Malaysia 2005-2007). Approximately 5,000 
Malaysian women aged between 30 and 60 years are diagnosed with breast 
cancer every year, and approximately 50% of these women are relatively young 
and below 50 years of age (Lim et al., 2008). 
 Unlike advanced disease, breast cancer is potentially curable if detected 
early (Wolff, 2000). Treatment of early stage breast cancer following surgery 
may involve adjuvant therapy consisting of systemic endocrine therapy and/or 
chemotherapy to prevent or delay tumor recurrence. The ultimate goal of 
adjuvant endocrine therapy is to treat early breast cancer successfully with 
minimal adverse effects. 
 The introduction of aromatase inhibitors (AIs) as an adjuvant treatment 
for postmenopausal women with hormone receptor-positive breast cancer has 
significantly changed the management of this disease. These agents are 
commonly used in place of or together with tamoxifen because of the 
demonstrated improvement in disease-free survival compared to the use of 
tamoxifen alone (Burstein et al., 2010). In postmenopausal women with 
hormone receptor–positive disease, AIs (such as anastrozole, letrozole and 
exemestane) have become standard of care as an adjuvant treatment aimed at 
preventing tumor relapse. Anastrozole is the only third-generation AI with 
available data as an adjuvant treatment for early breast cancer in 
postmenopausal women. Initial and updated results from the Arimidex, 
Tamoxifen alone or in combination (ATAC) trial confirmed that anastrozole was 
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more effective than tamoxifen for postmenopausal women with hormone-
responsive tumors (Tobias, 2004).  
 Magnetic resonance imaging (MRI) of the breast is often used following 
breast cancer surgery to monitor disease recurrence (Brennan et al., 2010). 
Recent studies have suggested that background parenchymal enhancement 
(BPE) of normal breast parenchyma is useful in breast cancer risk prediction 
(King et al., 2012a) and in treatment response and outcome assessments (King 
et al., 2012b). Although it has been postulated that BPE on MRI is related to 
vascular supply and permeability, the precise causes of differences in 
enhancement between and within individuals during their lifetime are not well 
understood.  
The risk of breast cancer for women with increased breast density is 
reported to be four to six times higher than that in women with less dense 
breast tissue (Harvey and Bovbjerg, 2004). Treatment with anastrozole 
decreases recurrence rates and is associated with a higher chance of disease-
free survival for breast cancer patients following a reduction in BPE. Thus, BPE 
is used as an indicator of the response to hormonal treatment in breast cancer 
patients. Evidence suggests that hormonally sensitive physiological changes 
that occur in the breast may be reflected by variations in BPE during the 
menstrual cycle (Kuhl et al., 1997). Another study indicated an increased BPE 
in women on hormone replacement therapy (Hussain et al., 1999) but a 
decreased BPE among patients taking anti-estrogen medications, including 
tamoxifen (King et al., 2012b), raloxifene (Eng-Wong et al., 2008) or toremifene 
(Oksa et al., 2009), indicating that BPE is a good indicator of the treatment 
response to hormones and may be used to aid breast cancer diagnosis. 
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 Although anastrozole is extensively used for breast cancer treatment, 
several adverse effects have been reported with its use, including the risk of 
osteoporosis, falls and fractures (Chen et al., 2009, Chen et al., 2005a, Chen et 
al., 2005b, Kanis et al., 1999). Many authors have suggested that honey, which 
is produced via complex enzymatic processes from nectar and saccharine 
exudates from various floral sources, has high antioxidant activity (Lurlina, 
2009, Pyrzynska, 2009, Yao, 2003) with good potential to prevent the 
development of cancer (Valko et al., 2007). However, to the best of our 
knowledge, its use as an adjuvant to modern therapy has not been investigated. 
 Several types of polyphenols in honey have been reported to exert 
antiproliferative activity against different types of cancer (Jaganathan and 
Mandal, 2009). An example of a honey with such properties is Tualang Honey 
(TH), a wild jungle honey produced by Apis dorsata bees, which make their 
hives on tall Koompassia excelsa (Tualang) trees in tropical rainforests (Nasir et 
al., 2010, Tan et al., 2009). The main active constituents in TH from Malaysia 
are phenolic acids and polyphenols (MI Khalil et al., 2011). In a preliminary 
study, TH was reported to confer positive modulatory effects on carcinogen 
(7,12-dimethylbenz(α)anthracene)-induced breast cancer in rats (Kadir et al., 
2013), indicating its potential as an anticancer therapy. The aim of this study 
was to investigate whether TH is a useful adjuvant to anastrozole in 
postmenopausal women. 
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3.3 Methodology 
 The main objective of this study is to investigate if treatment with TH 
influences BPE in postmenopausal women with prior history of breast cancer 
treated with anastrozole. Comparison of BPE of non-affected breast between 
control and intervention group were made pre and post treatment.  
 
3.3.1 Patient and Study Design  
 Ethical approval was obtained from the Human Research Ethics 
Committee of Universiti Sains Malaysia (USM), 
USMKK/PPP/JEPeM/[260.3(21)], which complies with the Declaration of 
Helsinki. This randomized controlled trial was conducted for 1.5 years (from 
October 2014 until April 2016) in the Oncology Clinic, Hospital USM, Kubang 
Kerian, Kelantan, Malaysia. A total of 22 patients were recruited and then 
divided into the control (n=10) and intervention (n=12) groups. Postmenopausal 
women with stage I-III unilateral estrogen receptor (ER)- and/or progesterone 
receptor (PgR)-positive breast cancer who received anastrozole treatment for 
less than a year were included in the study. Patients with a history of allergy to 
TH, who took over-the-counter supplements such as honey or herbs, who 
received hormone replacement therapy or who presented with liver or renal 
impairments were excluded.  
 Patients who consented to participate in the study were asked to provide 
written informed consent. Patients were randomized based on a block size of 
four using a computer-generated program. The patients were randomly 
assigned into either the control or intervention group. Patients in the control 
group received anastrozole (1 mg) daily, while patients in the intervention group 
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received anastrozole (1 mg) and TH (20 g) daily. The TH supplements were 
individually packaged in aluminum foil containing a fixed amount of honey in 
order to standardize the administered amount. The dose of TH in this study was 
based on a previous study conducted by Nik Hazlina et al. (2012). In addition, 
supplement packages were counted at the end of the study to ensure that the 
patients complied with the treatment regimen. The BPE of the non-affected 
breast in the control and intervention groups was compared before (at baseline) 
and after treatment (after six months). Patients were allowed to withdraw from 
the study at any time.The dose of TH in this study is based on a previous study 
conducted by Nik Hazlina et.al. (2012). 
 
 
3.3.2 MRI Protocol 
 Breast MRI with intravenous gadopentetate dimeglumine (Magnevist®) 
was performed using a Philips Achieva 3.0T X-Series MRI at the Department of 
Radiology, USM, on the first (0 months) and second visits (six months). The 
patient was placed in a prone position, and a breast coil was applied to the 
breasts. The standard imaging protocol included a localizing sequence, followed 
by a sagittal T1-weighted fat-saturated sequence performed before and after 
intravenous injection of Magnevist® (15 ml) via an in-dwelling intravenous 
catheter and a subsequent saline flush (10 ml). The slice thickness was 3 mm. 
Following image acquisition, the pre-contrast images were subtracted from the 
contrast images on a pixel-by-pixel basis to generate a maximum intensity 
projection (MIP). All MRI images were reviewed on a high resolution PACS 
monitor (Centricity, GE Healthcare). 
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3.3.3 MRI Interpretation 
 All images were independently reviewed by a breast imaging radiologist 
who was blinded to the study group. A combination of pre- and post-contrast T1 
fat-saturated images and MIP images was used to determine the BPE. For each 
MRI examination, BPE was prospectively assigned into one of four categories in 
accordance with the anticipated BIRAD MRI lexicon classification system: 
“minimal” (<25% of glandular tissue demonstrating enhancement), “mild” (25%–
50% enhancement), “moderate” (50%–75% enhancement), or “marked” (>75% 
enhancement) (Figure 1). The pre- and post-treatment breast MRI results were 
compared side-by-side to evaluate the changes in BPE, which increased the 
sensitivity since images could be compared simultaneously (King et al. (2012a). 
 
 
3.3.4 Statistical Analysis 
 Statistical analysis was performed using SPSS (version 18, SPSS Inc., 
Chicago, IL, USA). The data are presented as the mean ± S.D. However, if the 
data were not normally distributed, the median and inter-quartile range were 
calculated. Data normality was verified using the Shapiro-Wilks test. A side-by-
side comparison of BPE before and six months following treatment was utilized 
to determine the changes in BPE. The sign test was used to identify significant 
differences in the number of women with BPE changes. Categorical data were 
compared using chi-square and Fisher’s exact tests. A p value <0.05 was 
considered statistically significant.  
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3.4 Results 
3.4.1 Patient Characteristics 
 A total of 40 postmenopausal women with unilateral breast cancer (stage 
I to III) were assessed for eligibility for this study. Ten subjects have to be 
excluded [claustrophobia (n=7), inconsistent history of bilateral breast cancer 
(n=1), hip implant (n=1) and refused MRI (n=1)]. From the 30 patients recruited, 
seven dropped out due to refusal of MRI follow up (n=4), while three patients 
were non-compliant with the honey regimen. A patient passed away due to 
disease. As a result, a total of 22 patients aged 50 to 76 years were recruited. 
Among these patients, 10 were randomly allocated to the control group 
(anastrozole only), while 12 were placed in the intervention group (honey 
supplement and anastrozole); all patients received treatment and were followed 
for six months. 
 Patient characteristics (n=22) are shown in Table 1. The majority of the 
patients were Malays (90.9%), which reflects the demography of the local 
population; the remaining patients were Chinese. The mean patient age was 59 
± 5.9 years at the time the baseline MRI was taken, and the mean menopausal 
age was 50 ± 3.0 years; all patients experienced natural menopause.  
 
3.4.2 Background Parenchyma Enhancement Changes 
 Based on the MRI findings, the patient’s BPE was assigned one of 
several different categories. In the control group, the majority (90.0%) of the 
women had a stable BPE, but 10% showed a decrease in BPE (Table 2). The 
difference between the number of patients with decreased and stable BPE was 
not statistically significant (p=0.317). Approximately 25% of the patients with a 
moderate BPE at baseline showed a reduction in BPE to mild (Figure 2). None 
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of the women with minimal (n=1), mild (n=2) or marked (n=3) BPE showed any 
change in BPE.  
 In the intervention group, 41.7% had a decrease in BPE, while 58.3% did 
not show any BPE change (p=0.034) following treatment (Table 3). TH 
improved the BPE by a single category in four women and by two categories in 
one woman (Figure 3). Among the women who had a moderate BPE prior to 
treatment, 29% experienced a decrease in BPE to mild after treatment. 
 
 
 
                                                     
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
